deltatrials
Completed NA INTERVENTIONAL 2-arm NCT00492115

Cognitive Benefits of Treating Sleep Apnea in Parkinson's Disease (TAP)

Cognitive Benefits of Treating Sleep Apnea in Dementia

Sponsor: National Institute on Aging (NIA)

Updated 7 times since 2017 Last updated: Jul 2, 2019 Started: Jul 31, 2007 Primary completion: May 31, 2013 Completion: May 31, 2013
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

A NA clinical study on Parkinson's Disease and Sleep Disordered Breathing, this trial is completed. The trial is conducted by National Institute on Aging (NIA) and has accumulated 7 data snapshots since 2007. Longitudinal tracking of this trial contributes to a broader understanding of treatment development timelines.

Study Description(click to expand)

This study will examine the effect of three weeks vs. six weeks of CPAP treatment on cognitive functioning and sleep in patients with Parkinson's disease and sleep apnea. It is designed as a randomized, double blind, placebo-controlled trial of CPAP. As a comparison group, half the patients will first be randomly assigned to three weeks of shamCPAP, followed by three weeks of therapeutic CPAP treatment. Sleep, functional outcome and mood questionnaires and a repeatable neuropsychological test battery, chosen to be sensitive to the type of changes we expect to find in memory and cognitive function, will be administered before the start of treatment, after three weeks, and after six weeks of treatment.

This study will examine the effect of three weeks vs. six weeks of CPAP treatment on cognitive functioning and sleep in patients with Parkinson's disease and sleep apnea. It is designed as a randomized, double blind, placebo-controlled trial of CPAP. As a comparison group, half the patients will first be randomly assigned to three weeks of shamCPAP, followed by three weeks of therapeutic CPAP treatment. Sleep, functional outcome and mood questionnaires and a repeatable neuropsychological test battery, chosen to be sensitive to the type of changes we expect to find in memory and cognitive function, will be administered before the start of treatment, after three weeks, and after six weeks of treatment.

Status Flow

~Jan 2017 – ~Jun 2018 · 17 months · monthly snapshotCompleted~Jun 2018 – ~Jul 2018 · 30 days · monthly snapshotCompleted~Jul 2018 – ~Aug 2019 · 13 months · monthly snapshotCompleted~Aug 2019 – ~Jan 2021 · 17 months · monthly snapshotCompleted~Jan 2021 – ~Jul 2024 · 42 months · monthly snapshotCompleted~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshotCompleted~Sep 2024 – present · 19 months · monthly snapshotCompleted

Change History

7 versions recorded
  1. Sep 2024 — Present [monthly]

    Completed NA

  2. Jul 2024 — Sep 2024 [monthly]

    Completed NA

  3. Jan 2021 — Jul 2024 [monthly]

    Completed NA

  4. Aug 2019 — Jan 2021 [monthly]

    Completed NA

  5. Jul 2018 — Aug 2019 [monthly]

    Completed NA

Show 2 earlier versions
  1. Jun 2018 — Jul 2018 [monthly]

    Completed NA

  2. Jan 2017 — Jun 2018 [monthly]

    Completed NA

    First recorded

Jul 2007

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • National Institute on Aging (NIA)
  • University of California, San Diego
Data source: University of California, San Diego

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations